IRADIMED has pulled back in the short term after a strong multi year run. This puts the spotlight squarely on whether the current share price is properly anchored to the cash it can generate. With the analysis lens fixed on its cash flows, the question is how the recent history in the stock lines up with the intrinsic value suggested by a Discounted Cash Flow (DCF) approach.
-
Over the past 5 years the stock has returned about 121.7%, which raises the question of how much future cash generation is already reflected in the price.
-
The company's ability to convert its MRI compatible equipment sales into consistent free cash flow can shape how reliable any intrinsic value estimate based on its cash flows will be.
-
What if you looked at IRADIMED through its earnings instead? See why IRADIMED's 42.5x P/E tells a different valuation story .
The stock's next move may depend on whether today's price for IRADIMED is well supported by the cash flows implied in its intrinsic value estimate.
If you want to test the same cash flow question across a wider field, compare IRADIMED with companies in the 29 high quality undervalued stocks .
Does IRADIMED Look Fairly Valued on Cash Flow?
The Discounted Cash Flow (DCF) approach used here projects what IRADIMED might generate for shareholders in future and then brings those cash flows back to today. Latest twelve month free cash flow sits at about $20.0 million, which gives the model a concrete starting point rather than relying only on long range assumptions.
Analysts feeding into this DCF expect IRADIMED's free cash flow to grow from that recent base to higher annual levels over the next decade, so the model assumes a business that is still adding cash rather than shrinking it. Those projected dollars are then discounted and compared with the current share price of $76.68. On that basis the DCF puts IRADIMED's estimated intrinsic value broadly in line with the market price. This suggests the recent pullback has not clearly pushed the stock into either bargain territory or a clear premium on the cash flow view, which is why the detail in the full DCF remains important to judging whether the business looks appealing at today's terms. Find out what IRADIMED could be worth using our Discounted Cash Flow (DCF) estimate .
The IRADIMED Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the DCF puzzle for IRADIMED leaves off and spell out which combinations of growth, profitability and earnings power would need to play out for the share price to sit meaningfully above or below where it trades today, on the Community page. Each one links its number to a clear view on how IRADIMED's growth path, margins and main risks might evolve, so you can revisit those views as fresh information comes through.
One of the top community narratives on IRADIMED: 35% undervalued
"Early ordering patterns that skew toward higher priced four channel 3870 quad systems and an average selling price uplift of around 20%..."
Discover why this Narrative puts IRADIMED at 35% undervalued .
One more IRADIMED check that belongs beside the cash flow math
Price and projected cash tell only part of the IRADIMED story, because the track record and pay packets of the people steering the business can heavily influence how those numbers evolve over time. See who runs IRADIMED and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include IRMD .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
